The $100 Billion Question: Why AMR Gets Less Attention Than It Deserves
13 November 2025
Antimicrobial resistance (AMR) is projected to cause 10 million deaths annually by 2050, rivaling current global cancer mortality and threatening the safety of routine surgeries, childbirth, and cancer treatment itself. Despite already causing an estimated 1.27 million deaths each year, AMR receives only a fraction of the funding, political attention, and media coverage directed toward other major global health threats.
Unlike pandemics that emerge through visible crises, AMR develops gradually across healthcare, agriculture, and environmental systems, making it harder to communicate, measure, and sustain as a public priority. The challenge is compounded by an “attribution problem,” where deaths caused by drug-resistant infections are often recorded as pneumonia or sepsis rather than resistance itself, obscuring the true scale of the crisis.
Beyond the science, AMR also exposes a growing market failure in global health innovation. Several antibiotic developers have gone bankrupt despite bringing approved drugs to market, highlighting the limitations of traditional pharmaceutical incentives and the need for alternative funding and policy models.
This article explores:
Why AMR remains underfunded and overlooked despite projections that place it among the leading global causes of death by mid-century.
How the “attribution problem” and the slow-moving nature of resistance contribute to persistent public and political inattention.
Why antibiotic development has become economically unsustainable under current pharmaceutical market structures.
How global attention toward infectious disease threats is shaped by communication networks, advocacy infrastructure, and geopolitical visibility rather than mortality alone.
The role of alternative funding initiatives such as CARB-X, GARDP, and the AMR Action Fund in supporting antibiotic innovation outside traditional commercial models.
Why closing the AMR gap is ultimately a communication challenge as much as a scientific one, requiring strategies that translate technical evidence into public urgency and sustained policy action.
The Numbers That Don't Lie
The disparity becomes immediately clear when comparing health burden against investment (see accompanying graphic). AMR causes roughly twice as many deaths annually as HIV/AIDS, yet receives only about 15% of the funding. Cancer research attracts $25-30 billion annually while AMR receives approximately $1.7 billion from public and philanthropic sources [1-4].
“In the century since Alexander Fleming stumbled across penicillin in a laboratory in London, antibiotics have become a mainstay of medicine, transforming once-deadly infections into treatable and curable conditions. Antimicrobial resistance threatens to unwind that progress, making it without question one of the most pressing health challenges of our time.”
— Dr. Tedros Adhanom Ghebreyesus, WHO Director-General
These figures reveal only part of the story. The 1.27 million represents deaths directly attributable to drug-resistant infections where resistance was the primary factor. An additional 4.95 million deaths annually are associated with AMR, meaning infections where resistance played a contributing role [3].
Looking ahead, projections suggest AMR could cause 10 million deaths annually by 2050, matching current cancer mortality [9]. The O'Neill Review estimated cumulative economic costs could reach $100 trillion between now and 2050 [9]. More recent modelling indicates that between 2025 and 2050, AMR will lead directly to more than 39 million deaths cumulatively [10].
AMR already threatens medical procedures many consider routine. Joint replacements, cesarean sections, chemotherapy, and organ transplants all depend on effective antibiotics to prevent infections. Without them, modern medicine doesn't just become more challenging - much of it becomes impossible.
Despite these projections, AMR continues receiving dramatically less overall attention and resources than health threats with comparable mortality. Understanding why requires examining the structural forces that make AMR uniquely invisible.
The Invisibility Problem
Unlike pandemics that strike suddenly, AMR is a slow-developing crisis. There's no single outbreak moment, no dramatic surge, no clear starting point that captures attention. Resistance builds gradually through accumulated antibiotic misuse, agricultural practices, and environmental contamination. This temporal pattern makes generating urgency genuinely difficult.
The attribution challenge compounds this invisibility. When a patient dies of pneumonia, the death certificate typically lists pneumonia or sepsis, not antimicrobial resistance. The underlying issue, that bacteria resisted treatment, often becomes a medical record footnote rather than a reported statistic. Without death tolls clearly linked to AMR, the crisis lacks the immediate impact of diseases with more straightforward causation.
“AMR doesn't just threaten to make the medicines on which we depend less effective; it's happening now. What we're discussing is not merely the risk of people dying because of superbug infections - they are dying now, 1.3 million people every year.”
— Dr. Tedros Adhanom Ghebreyesus, WHO Director-General
The complexity barrier presents another obstacle. AMR isn't caused by a single pathogen or transmitted through one route. It emerges from intersecting systems: human medicine, veterinary practice, agriculture, and environmental contamination. Explaining this interconnected web doesn't compress into soundbites or simple public health messages. Understanding AMR requires systems thinking by recognizing how livestock antibiotic use affects human health, how pharmaceutical waste in waterways accelerates resistance, how inadequate hospital infection control creates resistant pathogen reservoirs.
The market failure represents perhaps the most significant structural barrier. New antibiotics aren't profitable investments. Many pharmaceutical companies have abandoned antibiotic development because the economic model fails. Unlike drugs for chronic conditions that patients take daily for years, antibiotics are, appropriately, used sparingly and briefly. Even successful new antibiotics are often held in reserve as last-resort options, further limiting revenue. Several antibiotic developers have declared bankruptcy despite having regulatory-approved products [11], a signal that has driven more companies away from the field entirely.
These factors combine into a "perfect storm of inattention": a threat that's too gradual to feel dramatic, too complex to explain simply, too diffuse to attribute clearly, and too economically unappealing to attract commercial investment. The result is a major health threat operating largely outside public awareness despite its substantial and growing impact.
This isn't merely theoretical. The same pattern plays out globally, regardless of geography or economic resources.
When Attention Does Arrive: The Global Pattern
The pattern repeats across continents. India's antibiotic resistance crisis gained international attention only after the NDM-1 gene discovery in 2008, when resistance mechanisms had already spread globally through medical tourism [12,13]. Today, pharmaceutical waste from production facilities contaminates waterways with antibiotic concentrations higher than therapeutic doses [14], yet sustained funding remains elusive despite India's disproportionate share of the global resistance burden.
South Africa carries one of the world's highest MDR-TB burdens, amplified by HIV creating large immunocompromised populations [15]. Despite clear data and known interventions, the chronic nature of TB makes it difficult to maintain political priority against more acute health threats.
Southeast Asia's artemisinin-resistant malaria gained significant resources, but primarily because malaria already had established advocacy networks and funding infrastructure [16]. Meanwhile, equally serious resistance in gonorrhea and typhoid in the same region receives far less attention. The lesson: attention follows existing infrastructure, not necessarily threat scale.
Even wealthy nations struggle. The United States sees 2.8 million resistant infections annually, yet AMR funding remains a fraction of investment in comparable health priorities [17]. Europe faces rising carbapenem resistance but fragmented coordination across member states.
The universal pattern: AMR gains attention only at crisis levels, and even then, sustaining focus proves difficult. Each region demonstrates that the fundamental challenge isn't geographic or economic, it's making the invisible visible and the chronic urgent.
The Communication Challenge
The gap between AMR's impact and its funding isn't a scientific problem as researchers have delivered compelling evidence. The challenge is translating that evidence into sustained action.
We understand resistance mechanisms. Surveillance systems track spread. Interventions are validated. Economic projections are documented. Yet this knowledge hasn't translated into proportional funding or political priority. The disconnect isn't in the science but in how that science reaches decision-makers.
Reframing matters. "Antimicrobial resistance" is technical jargon. "Threat to modern medicine" conveys actual stakes. The issue isn't just harder-to-treat infections, it's that cesarean sections, chemotherapy, and joint replacements become too dangerous to perform. This reframing makes AMR personal. Someone who feels unaffected by resistant bacteria suddenly recognizes relevance when they learn their upcoming surgery depends on effective antibiotics.
Making the invisible visible requires strategic science communication - visual storytelling and clear narratives that explain complexity without requiring technical expertise. For pharmaceutical and biotech organizations, this extends beyond public education to stakeholder engagement. Investors need to understand why antibiotic development requires different economic structures. Policymakers need clear explanations of why subscription models make fiscal sense.
Economic framing opens doors. The $100 trillion projection matters not just as statistics but as positioning. When framed as economic threat alongside health threat, AMR enters different conversations. Finance ministers pay attention when shown how AMR could eliminate GDP gains. This opens funding streams beyond traditional health budgets.
Research shows messages combining threat awareness with concrete action steps generate better responses than fear alone [18]. Effective communication pairs urgency with agency, not just "AMR is a problem" but "here's what we can do." Not just alarming statistics but solutions already working.
Science communicators, medical writers, and health communication specialists play a critical role in closing this gap by translating research into policy briefs that drive legislation, developing public messaging that changes behavior, and helping organizations build compelling cases for AMR investment. Strategic communication isn't just about disseminating information; it's about targeting the stakeholders who control funding, shape policy, and sustain long-term commitment with messages designed to convert attention into action.
Numerous organizations are already demonstrating what's possible through grassroots engagement. In India, the Global Antibiotic Resistance Partnership (GARP) and the Indian Initiative for Management of Antibiotic Resistance (IIMAR) work with communities to promote prudent antimicrobial use, while initiatives like the Red Line Campaign help the public identify prescription-only antibiotics. ReAct Asia Pacific's "Antibiotic Smart Communities" project in Kerala partners with local self-government institutions and women's self-help groups to build community ownership of AMR solutions. In Rwanda, the youth-led Oazis Health Initiative uses e-learning platforms to train healthcare workers in underserved communities. Students Against Superbugs Africa empowers young people as advocates across the continent. South Africa's South African Antibiotic Stewardship Programme (SAASP) coordinates advocacy and stewardship teams across public and private sectors.
These community-level efforts demonstrate that AMR communication works when it's culturally relevant, locally owned, and sustained beyond annual awareness campaigns. Yet their combined reach remains limited. Scaling these models requires the same strategic investment that research and surveillance receive.
What Happens Next
The data is clear: AMR deserves substantially more attention and resources than it currently receives. The research exists. The interventions are validated. The economic analysis is documented. So why does the gap persist?
Because this isn't fundamentally a scientific challenge but rather a communication challenge. And that's actually encouraging, because communication challenges have solutions within reach.
For researchers: Your data is compelling, but it needs effective translation. Partnering with science communicators who can convert findings into narratives resonating with policymakers, funders, and public audiences extends impact beyond academic journals.
For science communicators: AMR needs expertise in making invisible threats visible and complex systems understandable. Strategic visual communication, clear messaging frameworks, and stakeholder-specific narratives can shift how this crisis is perceived and prioritized.
For pharmaceutical and biotech organizations: The economic rationale for AMR investment needs clearer articulation by moving beyond technical descriptions to explaining why antibiotic innovation requires different business models, why pull incentives make economic sense, and how subscription models can protect both public health and commercial viability.
For policymakers: Proportional response requires proportional funding. The challenge is sustaining attention long enough to implement comprehensive solutions like early-stage R&D support, pull incentives, strengthened surveillance, improved access in resource-limited settings.
What's already working: Several organizations have demonstrated that alternative funding models succeed when commercial incentives fail. CARB-X, launched in 2016 and funded by governments and foundations, has supported 92 antibiotic products that might otherwise have stalled [22,23]. GARDP completed the first Phase 3 antibiotic trial sponsored by a non-profit, proving alternative models can navigate complex regulatory pathways [24,25]. The AMR Action Fund represents a $1 billion investment from over 20 pharmaceutical companies, WHO, and the European Investment Bank [26]. Most recently, the Gates Foundation, Novo Nordisk Foundation, and Wellcome Trust launched the Gram-Negative Antibiotic Discovery Innovator with $50 million [27].
These initiatives show what's possible when funders prioritize public health over commercial returns. They've sustained research pipelines, proven non-commercial models work, and established access frameworks for low-resource settings. Yet their combined funding remains a fraction of what diseases with comparable mortality receive.
The 2024 UN High-Level Meeting on AMR brought world leaders together for commitments to action [20]. Several countries are piloting subscription models and innovative financing mechanisms. The UK's updated National Action Plan, Germany's reserve antibiotic pricing reforms, and increasing G7 coordination all signal progress [21].
But momentum requires sustained communication matching threat scale. We need communication infrastructure that keeps AMR visible, stakeholders engaged, and funding flowing even when the crisis doesn't present with emergency urgency.
The $100 billion question has a clear answer: AMR deserves dramatically more attention and resources. Organizations like CARB-X and GARDP prove alternative models can work. The gap between what we know and what we're doing isn't about lacking solutions but rather about lacking the communication infrastructure to turn knowledge into sustained action.
That gap is closeable. Better framing, clearer narratives, strategic targeting, and visual storytelling are tools available now. The data supports urgent action. The economics demand it. The question is whether we'll deploy these communication tools at the scale and speed the crisis demands, before projections become reality, before the antibiotics that transformed medicine in the 20th century fail us in the 21st.
References
Lancet Oncology (2023). Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments. The Lancet Oncology, 24(6), 636-645.
Nature Index (2024). Are key funders of cancer research slowing down their spending?
Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, 399(10325), 629-655.
WHO & Global AMR R&D Hub (2023-2024). Incentivising the development of new antibacterial treatments: Progress reports.
O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance.
Naghavi, M., et al. (2024). Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. The Lancet, 404(10459), 1199-1226.
Outterson, K., et al. (2021). Accelerating global innovation to address antibacterial resistance. Annals of the New York Academy of Sciences, 1495(1), 3-20.
Laxminarayan, R., et al. (2013). Antibiotic resistance—the need for global solutions. The Lancet Infectious Diseases, 13(12), 1057-1098.
Kumarasamy, K.K., et al. (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK. The Lancet Infectious Diseases, 10(9), 597-602.
WHO (2023). Global Tuberculosis Report 2023.
Wi, T., et al. (2017). Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance. PLoS Medicine, 14(7), e1002344.
CDC (2019). Antibiotic Resistance Threats in the United States, 2019.
Witte, K., & Allen, M. (2000). A meta-analysis of fear appeals. Health Education & Behavior, 27(5), 591-615.
UN General Assembly (2024). Political Declaration of the High-Level Meeting on Antimicrobial Resistance.
WHO & Global AMR R&D Hub (2024). G7 Progress Report on Incentivising Antibacterial Treatments.
Outterson, K., et al. (2023). CARB-X Annual Report. Boston University.
Boston University School of Law (2023). CARB-X receives global funding in fight against antimicrobial resistance.
Piddock, L.J.V., et al. (2022). Nonprofit drug development model is part of the AMR solution. Clinical Infectious Diseases, 74(10), 1866-1873.
GARDP (2024). Global Antibiotic Research and Development Partnership Annual Reports.
IFPMA (2020). AMR Action Fund. International Federation of Pharmaceutical Manufacturers and Associations.
Gates Foundation, Novo Nordisk Foundation, & Wellcome (2025). Philanthropic Partnership Launches Gram-Negative Antibiotic Discovery Innovator.
